- Home
- CISO vs CVKD Comparison
CISO vs CVKD Comparison
Compare CISO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISO | CVKD |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 20.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CISO | CVKD |
|---|---|---|
| Price | $0.46 | $6.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 647.9K | 79.8K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,743,266.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $6.42 |
| 52 Week High | $2.80 | $22.90 |
Technical Indicators
Market Signals| Indicator | CISO | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 37.73 |
| Support Level | $0.46 | $6.42 |
| Resistance Level | $0.51 | $7.58 |
| Average True Range (ATR) | 0.05 | 0.79 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 41.28 | 19.87 |
Price Performance
Historical ComparisonAbout CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.